Literature DB >> 34342716

External evaluation of published population pharmacokinetic models of polymyxin B.

Ya-Qian Li1, Kai-Feng Chen1, Jun-Jie Ding2, Hong-Yi Tan3, Nan Yang1, Ya-Qi Lin1, Cui-Fang Wu1, Yue-Liang Xie1, Guo-Ping Yang3, Jing-Jing Liu4, Qi Pei5.   

Abstract

OBJECTIVES: Several population pharmacokinetics (popPK) models for polymyxin B have been constructed to optimize therapeutic regimens. However, their predictive performance remains unclear when extrapolated to different clinical centers. Therefore, this study aimed to evaluate the predictive ability of polymyxin B popPK models.
METHODS: A literature search was conducted, and the predictive performance was determined for each selected model using an independent dataset of 20 patients (92 concentrations) from the Third Xiangya Hospital. Prediction- and simulation-based diagnostics were used to evaluate model predictability. The influence of prior information was assessed using Bayesian forecasting.
RESULTS: Eight published studies were evaluated. In prediction-based diagnostics, the prediction error within ± 30% was over 50% in two models. In simulation-based diagnostics, the prediction- and variability-corrected visual predictive check (pvcVPC) showed satisfactory predictivity in three models, while the normalized prediction distribution error (NPDE) tests indicated model misspecification in all models. Bayesian forecasting demonstrated a substantially improvement in the model predictability even with one prior observation.
CONCLUSION: Not all published models were satisfactory in prediction- and simulation-based diagnostics; however, Bayesian forecasting improved the predictability considerably with priors, which can be applied to guide polymyxin B dosing recommendations and adjustments for clinicians.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  External evaluation; Polymyxin B; Population pharmacokinetics

Mesh:

Substances:

Year:  2021        PMID: 34342716     DOI: 10.1007/s00228-021-03193-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Analytical and functional determination of polymyxin B protein binding in serum.

Authors:  Henrietta Abodakpi; Jie Gohlke; Kai-Tai Chang; Diana S-L Chow; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 2.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

3.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

Review 4.  Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives.

Authors:  Femke de Velde; Johan W Mouton; Brenda C M de Winter; Teun van Gelder; Birgit C P Koch
Journal:  Pharmacol Res       Date:  2018-07-06       Impact factor: 7.658

5.  The motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research.

Authors:  Zejuan Wang; Gang Chen; Xiaona Liu; Chen Liu; Qingkun Song; Jin Wang
Journal:  Eur J Clin Pharmacol       Date:  2020-11-13       Impact factor: 2.953

6.  Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.

Authors:  Andrea L H Kwa; Tze-Peng Lim; Jenny G H Low; JingGuo Hou; Asok Kurup; Randall A Prince; Vincent H Tam
Journal:  Diagn Microbiol Infect Dis       Date:  2007-10-04       Impact factor: 2.803

7.  Pharmacokinetics of intravenous polymyxin B in critically ill patients.

Authors:  Alexandre P Zavascki; Luciano Z Goldani; Guoying Cao; Silvana V Superti; Larissa Lutz; Afonso L Barth; Fabiano Ramos; Márcio M Boniatti; Roger L Nation; Jian Li
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

8.  Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model.

Authors:  Pooja Manchandani; Jian Zhou; Kimberly R Ledesma; Luan D Truong; Diana S-L Chow; Jason L Eriksen; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

9.  Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients.

Authors:  Sean N Avedissian; Cristina Miglis; Christine J Kubin; Nathaniel J Rhodes; Michael T Yin; Serge Cremers; Michelle Prickett; Marc H Scheetz
Journal:  Pharmacotherapy       Date:  2018-07       Impact factor: 4.705

10.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

View more
  3 in total

1.  External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients.

Authors:  Nan Yang; Jing Wang; Yueliang Xie; Junjie Ding; Cuifang Wu; Jingjing Liu; Qi Pei
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

2.  Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients.

Authors:  Yue-Liang Xie; Xin Jin; Shan-Shan Yan; Cui-Fang Wu; Bi-Xiao Xiang; Hui Wang; Wu Liang; Bing-Chang Yang; Xue-Fei Xiao; Zhi-Ling Li; Qi Pei; Xiao-Cong Zuo; Yue Peng
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

3.  External evaluation of published population pharmacokinetic models of posaconazole.

Authors:  Shuqi Huang; Qin Ding; Nan Yang; Zexu Sun; Qian Cheng; Wei Liu; Yejun Li; Xin Chen; Cuifang Wu; Qi Pei
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.